INBRX 121
Alternative Names: INBRX-121Latest Information Update: 06 Jun 2024
At a glance
- Originator Inhibrx
- Class Antibodies; Antineoplastics; Cytokines; Immunotherapies; Interleukins
- Mechanism of Action Cytokine induced killer cell modulators; Immunologic cytotoxicity
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 30 May 2024 Inhibrx Biosciences acquires INBRX 121 from Inhibrx prior to May 2024
- 08 Apr 2022 Safety and pharmacodynamics data from preclinical studies in Cancer presented at the 113th Annual Meeting of the American Association for Cancer Research (AACR-2022)
- 01 Jan 2022 Preclinical trials in Cancer in USA (Parenteral)